|
MAJOR AFFECTIVE DISORDER 7
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Individuals with BPAD presented higher levels of A. actinomycetemcomitans and P. gingivalis, suggesting that periodontitis could be a co-morbidity frequently found in individuals with BAPD.
|
30207388 |
2019 |
|
MAJOR AFFECTIVE DISORDER 8
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Individuals with BPAD presented higher levels of A. actinomycetemcomitans and P. gingivalis, suggesting that periodontitis could be a co-morbidity frequently found in individuals with BAPD.
|
30207388 |
2019 |
|
MAJOR AFFECTIVE DISORDER 9
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Individuals with BPAD presented higher levels of A. actinomycetemcomitans and P. gingivalis, suggesting that periodontitis could be a co-morbidity frequently found in individuals with BAPD.
|
30207388 |
2019 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Localization of MDX-210 in tumor tissue was demonstrated in two patients.
|
7545221 |
1995 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Most MDI targets individually are significant markers of ER(+) cancer survival.
|
21641572 |
2011 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Most MDI targets individually are significant markers of ER(+) cancer survival.
|
21641572 |
2011 |
|
Behcet Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Neither prenatal exposure to BD- or BD+ significantly impacted overall PDI (P = .2449), MDI (P = .7886), or BRS (P = .6072) scores.
|
28068465 |
2017 |
|
Autistic Disorder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Next, a microglial developmental index (MDI) generated from gene expression patterns obtained from purified mouse microglia, was applied to human brain transcriptome datasets to test the hypothesis that variability in microglial development is associated with human diseases such as Alzheimer's and autism where microglia have been suggested to play a role.
|
28618077 |
2017 |
|
Diabetic Ketoacidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Notably, the increased risk of DKA was significant in trials comparing CSII with conventional insulin therapy, whereas only a nonsignificant trend toward an increased risk was observed in comparisons with basal-bolus MDI.
|
30945047 |
2019 |
|
Diabetes
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our finding indicated that MDI 301 offers the potential for repairing the faulty skin function arising from diabetes.
|
28423369 |
2017 |
|
Diabetes Mellitus
|
0.020 |
Biomarker
|
group |
BEFREE |
Our finding indicated that MDI 301 offers the potential for repairing the faulty skin function arising from diabetes.
|
28423369 |
2017 |
|
Muscular Dystrophy, Duchenne
|
0.010 |
Biomarker
|
disease |
BEFREE |
Patients affected by Duchenne muscular dystrophy (DMD) and dystrophic MDX mice were investigated in this study for their bone phenotype and systemic regulators of bone turnover.
|
21509823 |
2011 |
|
Diabetes, Autoimmune
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Patients belonging to the latter group may either carry mutations in genes different from those commonly found in PNDM/MDI or have developed an early-onset form of autoimmune diabetes.
|
21544516 |
2011 |
|
Advanced breast cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.
|
14676800 |
2003 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.
|
7545221 |
1995 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.
|
7545221 |
1995 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.
|
7545221 |
1995 |
|
Fibrosis, Liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
Restoration of SIRT1 protein was observed in the in vivo spontaneously liver fibrosis reversion model and in vitro MDI (isobutylmethylxanthine, dexamethasone, and insulin)-induced reversed stellate cells, and forced expression of SIRT1 also promoted the reversal of activated stellate cells.
|
26435214 |
2015 |
|
Chronic Obstructive Airway Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
Results confirmed the long-term safety and tolerability of GFF MDI 18/9.6 μg twice-daily in subjects with moderate-to-very severe COPD.
|
28427541 |
2017 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
rtCGM was superior to SMBG in reducing A1C, hypoglycemia, and other end points in individuals with T1D regardless of their insulin delivery method. rtCGM+MDI can be considered an equivalent but lower-cost alternative to sensor-augmented insulin pump therapy and superior to treatment with SMBG+MDI or SMBG+CSII therapy.
|
31530663 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
T2DM: Type 2 Diabetes Mellitus; HbA<sub>1C</sub>: Hemoglobin A<sub>1c</sub>; OHA: Oral Hypoglycemic Agents; STIT: Short-term Insulin Treatment; CSII: Continuous Subcutaneous Insulin Infusion; MDI: Multiple Daily Injections; PPG: Postprandial Plasma Glucose; FPG: Fasting Plasma Glucose; HOMA-b: Homeostasis Model Assessment of beta-cell function; TDD: Total Daily Insulin Dose; DI: Disposition Index; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; ROS: Reactive Oxygen Species; TNF: Tumor Necrosis Factor; GLP-1: Glucagon-like peptide-1; GIP: Glucose-dependent Insulinotropic Polypeptide; BMI: Body Mass Index; CV: Cardiovascular; DR: Diabetic Retinopathy; SU: Sulfonylurea; IGI: Insulinogenic Index.
|
30244600 |
2018 |
|
Severe chronic obstructive pulmonary disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
TELOS compared budesonide (BD)/formoterol fumarate dihydrate (FF) metered dose inhaler (BFF MDI), formulated using innovative co-suspension delivery technology that enables consistent aerosol performance, with its monocomponents and budesonide/formoterol fumarate dihydrate dry powder inhaler (DPI) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), without a requirement for an exacerbation history.In this phase III, double-blind, parallel-group, 24-week study (NCT02766608), patients were randomised to BFF MDI 320/10 µg (n=664), BFF MDI 160/10 µg (n=649), FF MDI 10 µg (n=648), BD MDI 320 µg (n=209) or open-label budesonide/formoterol DPI 400/12 µg (n=219).
|
30220648 |
2018 |
|
Coronary heart disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
The ACA-PI was positively correlated with the PDI and MDI scores in fetuses with CHDs (r<sup>2</sup> = 0.26, 0.20, P < 0.01).
|
29540791 |
2018 |
|
Hepatitis C
|
0.010 |
Biomarker
|
disease |
BEFREE |
The antiviral potential of BMS-936558 (MDX-1106) - a fully human anti-PD-1 monoclonal immunoglobulin-G4 that blocks ligand binding - was explored in a proof-of-concept, placebo-controlled single-ascending-dose study in patients (N = 54) with chronic HCV infection.
|
23717490 |
2013 |
|
Periodontitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The final multivariate logistic regression revealed that periodontitis was strongly associated with the total bacterial load (OR = 1.91; 95% IC = 1.0-1.99; P < 0.001) and the depressive phase of BPAD (OR = 28.94; 95% IC = 4.44-177.27; P < 0.001).
|
30207388 |
2019 |